Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Advancing gene therapy
for neurodegenerative ophthalmic diseases

GenSight Biologics Co-Founder José-Alain Sahel and colleague Botond Roska were awarded the 2024 Wolf Prize in Medicine for pioneering work on optogenetics -- the core technology of GS030
Award citation
MERIT OF DISTINCTION: abstract on "The Latest Data from Lenadogene Nolparvovec Gene Therapy Trials for Leber Hereditary Optic Neuropathy", presented by Dr. Nancy J. Newman of Emory University at the 2025 annual meeting of the American Academy of Neurology
S14: Distinction in Neuro-ophthalmology/Neuro-otology

Clinical trials

GS010; (lenadogene nolparvovec) is completing its clinical development while GS030 is currently running PIONEER Phase I/II
Check status

Our technologies

  • Gene Therapy
  • Mitochondrial Targeting Sequence (MTS)
  • Optogenetics
  • View our Technologies
  • Paris
  • New York City
GENSIGHT BIOLOGICS S.A.
74, rue du Faubourg Saint-Antoine
75012 Paris
FRANCE
Contact us
GENSIGHT BIOLOGICS Inc.
3 East 28th Street
New York, NY 10016
USA
Contact us
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page